181 related articles for article (PubMed ID: 27226843)
21. Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries?
Kim Y; Kwon HY; Godman B; Moorkens E; Simoens S; Bae S
Front Pharmacol; 2020; 11():970. PubMed ID: 32733238
[TBL] [Abstract][Full Text] [Related]
22. Forecasting drug utilization and expenditure: ten years of experience in Stockholm.
Linnér L; Eriksson I; Persson M; Wettermark B
BMC Health Serv Res; 2020 May; 20(1):410. PubMed ID: 32393238
[TBL] [Abstract][Full Text] [Related]
23. Pharmaceutical policy regarding generic drugs in Belgium.
Simoens S; De Bruyn K; Bogaert M; Laekeman G
Pharmacoeconomics; 2005; 23(8):755-66. PubMed ID: 16097838
[TBL] [Abstract][Full Text] [Related]
24. Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis.
Manova M; Savova A; Vasileva M; Terezova S; Kamusheva M; Grekova D; Petkova V; Petrova G
Front Pharmacol; 2018; 9():1070. PubMed ID: 30294275
[TBL] [Abstract][Full Text] [Related]
25. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
Theriaca; 2016; (43):9-61. PubMed ID: 27491172
[TBL] [Abstract][Full Text] [Related]
26. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
[TBL] [Abstract][Full Text] [Related]
27. The impact of generics and generic reference pricing on candesartan and rosuvastatin utilisation, price and expenditure in South Africa.
de Jager H; Suleman F
Int J Clin Pharm; 2019 Feb; 41(1):81-87. PubMed ID: 30478491
[TBL] [Abstract][Full Text] [Related]
28. Price Determinants of the Tendering Process for Pharmaceuticals in the Cyprus Market.
Petrou P; Talias MA
Value Health Reg Issues; 2015 Sep; 7():67-73. PubMed ID: 29698154
[TBL] [Abstract][Full Text] [Related]
29. Competition Between Biosimilars and Patented Biologics: Learning from European and Japanese Experience.
Bocquet F; Loubière A; Fusier I; Cordonnier AL; Paubel P
Pharmacoeconomics; 2016 Nov; 34(11):1173-1186. PubMed ID: 27412251
[TBL] [Abstract][Full Text] [Related]
30. The Expiry of Humira
Moorkens E; Godman B; Huys I; Hoxha I; Malaj A; Keuerleber S; Stockinger S; Mörtenhuber S; Dimitrova M; Tachkov K; Vončina L; Palčevski VV; Achniotou G; Slabý J; Popelková L; Kohoutová K; Bartels D; Laius O; Martikainen JE; Selke GW; Kourafalos V; Magnússon E; Einarsdóttir R; Adams R; Joppi R; Allocati E; Jakupi A; Viksna A; Greičiūtė-Kuprijanov I; Vella Bonanno P; Suttorp V; Melien Ø; Plisko R; Mardare I; Meshkov D; Novakovic T; Fürst J; Zara C; Marković-Peković V; Grubiša N; Befrits G; Puckett R; Vulto AG
Front Pharmacol; 2020; 11():591134. PubMed ID: 33519450
[No Abstract] [Full Text] [Related]
31. Projecting Pharmaceutical Expenditure in EU5 to 2021: Adjusting for the Impact of Discounts and Rebates.
Espin J; Schlander M; Godman B; Anderson P; Mestre-Ferrandiz J; Borget I; Hutchings A; Flostrand S; Parnaby A; Jommi C
Appl Health Econ Health Policy; 2018 Dec; 16(6):803-817. PubMed ID: 30088251
[TBL] [Abstract][Full Text] [Related]
32. Different Policy Measures and Practices between Swedish Counties Influence Market Dynamics: Part 1-Biosimilar and Originator Infliximab in the Hospital Setting.
Moorkens E; Simoens S; Troein P; Declerck P; Vulto AG; Huys I
BioDrugs; 2019 Jun; 33(3):285-297. PubMed ID: 30945207
[TBL] [Abstract][Full Text] [Related]
33. Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States.
Vogler S; Habl C; Bogut M; Voncina L
Croat Med J; 2011 Apr; 52(2):183-97. PubMed ID: 21495202
[TBL] [Abstract][Full Text] [Related]
34. The timelines for the price and reimbursement authorization in Italy 2018-2020.
Gallo V; Alessi E; Montilla S; Altamura G; Traversa G; Trotta F
Front Med (Lausanne); 2022; 9():1055359. PubMed ID: 36619645
[TBL] [Abstract][Full Text] [Related]
35. Projecting future drug expenditures--1996.
Santell JP
Am J Health Syst Pharm; 1996 Jan; 53(2):139-50. PubMed ID: 8653479
[TBL] [Abstract][Full Text] [Related]
36. Pharmaceutical expenditure on drugs for rare diseases in Canada: a historical (2007-13) and prospective (2014-18) MIDAS sales data analysis.
Divino V; DeKoven M; Kleinrock M; Wade RL; Kim T; Kaura S
Orphanet J Rare Dis; 2016 May; 11(1):68. PubMed ID: 27207271
[TBL] [Abstract][Full Text] [Related]
37. The distribution of sales revenues from pharmaceutical innovation.
Grabowski HG; Vernon J
Pharmacoeconomics; 2000; 18 Suppl 1():21-32. PubMed ID: 11151306
[TBL] [Abstract][Full Text] [Related]
38. Forecasting Ontario Oncology Drug Expenditures: A Hybrid Approach to Improving Accuracy.
Murray PM; Shalaby YA; Ieraci L; Borg E; Sniekers D; Esensoy AV; Arias J
Appl Health Econ Health Policy; 2020 Feb; 18(1):127-137. PubMed ID: 31724104
[TBL] [Abstract][Full Text] [Related]
39. Biosimilars: How Can Payers Get Long-Term Savings?
Mestre-Ferrandiz J; Towse A; Berdud M
Pharmacoeconomics; 2016 Jun; 34(6):609-16. PubMed ID: 26792791
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
